Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,659.89
(
-0.84%
)
US TECH 100
23,984.40
(
-0.61%
)
Dow Jones
46,457.17
(
-1.14%
)
Brent Oil
105.05
(
4.37%
)
Bitcoin
71,534.68
(
-3.25%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 74673

Tuesday, 03/17/2009 5:24:12 PM

Tuesday, March 17, 2009 5:24:12 PM

Post# of 257253
The ghost of Exanta? The FDA briefing doc for Xarelto has been influenced, perhaps unduly, by the liver toxicity that was the undoing of Exanta.

Xarelto is already approved in the EU; if it does not make it through the FDA in one piece, it will be a bad harbinger for the entire drug/biotech industry, IMO.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now